Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05421780
Other study ID # S16
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date June 29, 2022
Est. completion date July 2024

Study information

Verified date November 2023
Source National University of Singapore
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the glycaemic controlling effects of BSG and bio-transformed BSG-containing biscuits in Singapore adults with MetS. The investigators hypothesized that consumption of BSG and bio-transformed BSG containing biscuit will improve glycaemic control.


Description:

This is a double-blind, randomised, crossover experiment. During the 3-week, 19 subjects will participate in a 3 meal tolerance test (MTT). During each MTT session, all subjects are required to consume 90 g biscuits (either control, autoclaved BSG or bio-transformed BSG biscuits) and monitored over a period of 240 minutes. All three types of biscuits will be consumed at a randomised sequence during this 3-week period. Post-prandial blood glucose, insulin, lipid and amino acid responses, breath analysis, body composition, blood pressure, appetite assessment, and any other glycaemic biomarkers will be assessed.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 16
Est. completion date July 2024
Est. primary completion date December 13, 2022
Accepts healthy volunteers No
Gender All
Age group 35 Years to 85 Years
Eligibility Inclusion Criteria: - Male and female participants, aged 35-85 years old - English-literate and able to give informed consent in English - Willing to follow the study procedures - Meet any 3 of the 5 following NCEP-ATP III MetS criteria: waist circumference > 102 cm (male), > 88 cm (female) (For Asian population: Waist circumference > 90 cm (male), > 80 cm (female)); fasting glucose concentration = 100 mg/dL or on medication; triglyceride = 150 mg/dL or on medication; high density lipoprotein cholesterol (HDL) < 40 mg/dL (male), < 50 mg/dL (female); systolic or diastolic blood pressure > 130/85 mmHg or on medication); Exclusion Criteria: - Significant change in weight (= 3 kg body weight) during the past 3 months - Allergy to barley, wheat, corn, egg, or other ingredients found inside the biscuits. - Acute illness at the study baseline - Exercising vigorously* over the past 3 months. *Defined as having > 6 metabolic equivalents of exercise daily; approximately 20 mins of moderate intensity exercise (e.g. slow jogging) a day - Following any restricted diet (e.g. vegetarian) - Smoking - Have a daily intake of more than 2 alcoholic drinks per day - Taking dietary supplements or food which may impact the outcome of interests (e.g. fermented foods, probiotic supplement etc.) - Consumption of antibiotics over past 3 months. - Pregnant, lactating, or planning pregnancy in the next 6 months - Insufficient venous access to allow the blood collection - Prescribed and taking antihypertensive/cholesterol-lowering/ type-2 diabetic medication which started less than 3 years prior to the intervention participation - High current intake of fibre* from brown rice or wholemeal products. *High, moderate or low intake taken as = 6 servings, 4 - 5 servings, and = 3 servings daily respectively based on My Healthy Plate guidelines - High current intake of fibre* from vegetables. * High, moderate or low intake taken as = 2 servings, 2 servings, and = 1 serving respectively based on My Healthy Plate guidelines

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
autoclaved BSG-containing biscuits
Consumption of autoclaved BSG-containing biscuits as breakfast.
bio-transformed BSG-containing biscuits
Consumption of bio-transformed BSG-containing biscuits as breakfast.
control biscuits
Consumption of plain biscuits as breakfast.

Locations

Country Name City State
Singapore Yujing Xu Singapore

Sponsors (2)

Lead Sponsor Collaborator
National University of Singapore Ministry of Education, Singapore

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in blood glucose concentration Glucose concentration in the blood will be measured Every week (week 1, week 2 and week 3)
Primary Change in blood insulin concentration Insulin concentration in the blood will be measured Every week (week 1, week 2 and week 3)
Primary Change in blood triglyceride concentration Triglyceride concentration in the blood will be measured Every week (week 1, week 2 and week 3)
Primary Change in blood cholesterol concentration Total cholesterol concentration in the blood will be measured Every week (week 1, week 2 and week 3)
Primary Change in blood Low-density Lipoprotein-cholesterol (LDL) concentration Low-density Lipoprotein-cholesterol concentration in the blood will be measured Every week (week 1, week 2 and week 3)
Primary Change in High-density Lipoprotein-cholesterol (HDL) concentration High-density Lipoprotein-cholesterol concentration in the blood will be measured Every week (week 1, week 2 and week 3)
Primary Change in blood amino acid concentration Amino acid concentration in the blood will be measured Every week (week 1, week 2 and week 3)
Secondary Change in appetite assessed by visual analogue scale Visual analogue scale will be used to assess appetite. Every week (week 1, week 2 and week 3)
Secondary Change in breath CH4 and H2 concentrations CH4 and H2 concentrations will be measured by breath analyzer Every week (week 1, week 2 and week 3)
Secondary Change in weight and height Weight (in kilograms) and height (in meters) will be combined to report BMI in kg/m^2 Every week (week 1, week 2 and week 3)
Secondary Change in waist circumference Waist circumference (in cm) will be measured Every week (week 1, week 2 and week 3)
Secondary Change in blood pressure Systolic and diastolic blood pressure (in mmHg) will be measured by a blood pressure monitor. Every week (week 1, week 2 and week 3)
See also
  Status Clinical Trial Phase
Completed NCT05594446 - Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
Completed NCT03975309 - DHS MIND Metabolomics
Completed NCT01855399 - Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes N/A
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Recruiting NCT05007990 - Caregiving Networks Across Disease Context and the Life Course
Active, not recruiting NCT04420936 - Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program N/A
Recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Completed NCT04903496 - Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
Completed NCT01437592 - Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects Phase 1
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT03390179 - Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Recruiting NCT05294822 - Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes N/A
Completed NCT04427982 - Dance and Diabetes/Prediabetes Self-Management N/A
Completed NCT02356848 - STEP UP to Avert Amputation in Diabetes N/A
Completed NCT03292185 - A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects Phase 1
Active, not recruiting NCT05477368 - Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes N/A
Completed NCT04496401 - PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus Phase 4